Business
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics.
About this update from Quest Diagnostics Incorporated
[{"type":"text","content":"SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics.","length":515,"tagName":"p"},{"type":"image","alt":"questhealth.com logo (PRNewsfoto/Quest Diagnostics)","displaySize":"","headline":null,"caption":"questhealth.com logo (PRNewsfoto/Quest Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":190,"url":"https://media.zenfs.com/en/prnewswire.com/596f9c53c019a633fa68d8b76e9b4722"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k2mwruheEOCrSDbP9G.wCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/596f9c53c019a633fa68d8b76e9b4722","width":400,"height":190}},"href":"https://mma.prnewswire.com/media/2691025/Quest_Diagnostics_questhealth_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Details of the poster presentations are as follows:","length":51,"tagName":"p"},{"type":"text","content":"Title: Reproducibility and Clinical Concordance of a Tumor-Informed MRD Assay in Patients with Resected Colorectal Cancer from the DYNAMIC TrialsAbstract Number: 26 Lead Author: Jeanne Tie, MBChB, FRACP, MD Session Time and Date: 1/10/2026, 12:00 PM-1:30 PM (PST)","length":276,"tagName":"p","attribs":{}},{"type":"text","content":"Title: Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC).Abstract Number: 30 Lead Author: Eric Christenson, MDSession Time and Date: 1/10/2026, 12:00 PM-1:30 PM (PST)","length":281,"tagName":"p","attribs":{}},{"type":"text","content":"About ctDNA MRD ","length":15,"tagName":"p"},{"type":"text","content":"A growing body of research underscores the value of ctDNA-based MRD testing to identify residual or recurring cancer in solid tumors. By detecting trace amounts of tumor-derived DNA in the bloodstream, MRD testing can reveal mol...